ASHPEmergingSciences

Wow!🤩Great discussion about AI integration in academic training/pharmacy practice at the Emerging Sciences roundtable! If this topic is up your alley start your day tomorrow with us at 8 am in room 352 "Working Collaboratively with AI in Your Future Career"

Join the Emerging Sciences SAG today at 11:15 am on Level 3 in Room 349 to network and discuss PGX, AI and other trending issues related to trending R and D aspects of pharmacotherapy. 🔥🧬🧪

If you checked out the journal club last night with @storeyrx 👇👇check out these opportunities to learn more at Midyear 🔥

I’d like to extend my thanks to Drs Shay and Storey for providing top level tips for engaging in the operational aspects of gene therapy which will be a certain area of exponential growth! Thanks to all who tuned in!

Given the rapid growth associated with gene therapy, how can health-systems practice safe handling when current guidelines and standards are outdated?

How should health-system pharmacy leaders train their staff to handle gene therapy given the risk of occupational exposure?

@storeyrx Makes sense and I'm sure all the PA work needs some resource allocation too!

@ASHP_EmergSci Operationally, centers must ensure appropriate cold chain storage, trained personnel, and SOPs are in place.  Financially, centers need to be engaged with confirming benefits, prior authorization, and payor contracting. These all need confirmation prior to ordering gene therapy.

What are some of the barriers experienced with gene therapy management from both an operational and clinical perspective?

What advice do you have for health-system pharmacy leaders that are trying to on-board offering gene therapy at their site? How can they approach discussions with institutional leaders on financial planning?

@storeyrx Great tips!!

@ASHP_EmergSci ASGCT provides a landscape report quarterly to keep up with new publications and FDA approvals. There are many updates coming forth about the handling and safety of viral vector based gene therapies. ASHP continues to provide programming on gene therapy in various formats.

What recommendations do you have for health-system pharmacy leaders to keep up to date with new gene therapy approvals?

What are the pros and cons of the buy and bill vs. white bagging purchasing strategies for gene therapy?

Now for the $ questions... Approximately how much does gene therapy cost? Is gene therapy eligible for 340B pricing?

What disease states are gene therapies most commonly used in?

Let’s start with the basics. When was the first gene therapy FDA-approved? How many gene therapies are currently approved?

Welcome to tonight’s @ASHP_EmergSci Journal Club with Drs Blake Shay and Michael Storey @storeyrx I’m @nephpharm and I will be your host. I work on the nanoformulation side- so I’m excited to understand the pragmatic challenges/opportunities at the operational level!🧬🧑‍💼💉🧪

🔥🔥Tonight 8 PM EST- Dr. Blake Shay and Dr. Michael Storey @storeyrx will discuss the practical considerations gene therapy in the context of operational pharmacy practice pubmed.ncbi.nlm.nih.gov/38364866/🧬🧬 fda.gov/vaccines-blood…

It's true! @ASHP_EmergSci has another X journal club next week! Tune in for a great discussion on gene therapy with a focus on operational aspects with Drs. Blake Shay and Michael Story @storeyrx

Many thanks to @steve_smoke the great dialog and for giving some credibility to our emerging AI lexicons! Make sure you peruse the thread for great resources! Thanks for joining!

@steve_smoke Really comes down to life long learning in the end!

@ASHP_EmergSci My generation had an advantage when coming out of school - we grew up on computers. Your generation has a similar opportunity with AI. Play with AI chatbots and tools. Learn good and bad uses. This foundational experience will be essential to navigating applications to medicine.

Any final tips for student pharmacists who want to understand the AI landscape for medication use?